Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform
March 24, 2022 03:00 ET
|
Glycotope
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform Expansion of senior team to focus on drug discovery and developmentPlatform combines glycobiology...
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
February 01, 2022 02:00 ET
|
Glycotope
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH Berlin, Germany, February 1, 2022 - Glycotope GmbH, a biotechnology company developing antibodies against proteins...
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting
November 15, 2021 03:00 ET
|
Glycotope
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope Poster Presentation at the 2021 Society...
Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets
July 27, 2021 03:00 ET
|
Glycotope
NEWS RELEASE Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets Nijmegen, the Netherlands, Berlin, Germany – 27 July 2021 –...
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
June 04, 2021 09:00 ET
|
Glycotope
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, June 4, 2021 - Glycotope GmbH, a biotechnology company developing...
Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
April 30, 2021 02:00 ET
|
Glycotope
Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, April 30, 2021 - Glycotope GmbH, a biotechnology company...
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1
December 17, 2020 03:30 ET
|
Glycotope
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1 GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors. Berlin,...
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms
September 21, 2020 04:00 ET
|
Glycotope
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 -...
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
July 30, 2018 03:00 ET
|
Glycotope
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited...
Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies
December 22, 2017 05:40 ET
|
Glycotope
Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies · GATTO Study to Evaluate Gatipotuzumab and Tomuzotuximab in Advanced and/or Metastatic Solid...